Signal
Summit Therapeutics shares fall after surprise interim miss in ivonescimab trial
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-05-01 15:00 UTCUpdated 2026-05-01 16:28 UTC
rss
clinical_trialsdrug_developmentfda
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (3 domains)domains are deduped. counts indicate coverage, not truth.3 top sources shown
Overview
Summit Therapeutics experienced a sharp decline in share price following an unexpected interim analysis miss in its Harmoni-3 trial of ivonescimab, a PD-1xVEGF bispecific antibody.
Entities
Summit TherapeuticsivonescimabHarmoni-3 trial
Score total
1.02
Momentum 24h
3
Posts
3
Origins
3
Source types
1
Duplicate ratio
33%
Why now
- The interim analysis result was recently announced, triggering immediate market reaction.
- Ivonescimab was scheduled for a key presentation at the upcoming ASCO annual meeting.
- The trial outcome influences near-term clinical development and investor sentiment.
Why it matters
- Interim trial results can significantly impact biotech company valuations and development strategies.
- Ivonescimab’s trial outcome affects the competitive landscape for PD-1xVEGF bispecific therapies.
- The ASCO plenary spotlight underscores the trial’s high profile and the disappointment of the miss.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: high
Recurring claims
- Interim trial results can significantly impact biotech company valuations and development strategies.
- Ivonescimab’s trial outcome affects the competitive landscape for PD-1xVEGF bispecific therapies.
How sources frame it
- Fierce Pharma: neutral
Consolidated multiple reports into a concise narrative highlighting the clinical and market impact of the interim trial miss.
All evidence
All evidence
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
BioPharma Dive · biopharmadive.com · 2026-05-01 16:28 UTC
A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has sent Summit Therapeutics’ shares tumbling, casting a shadow over the company’s momentum as the...
Fierce Pharma (All) · fiercepharma.com · 2026-05-01 15:00 UTC
A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has sent Summit Therapeutics’ shares tumbling, casting a shadow over the company’s momentum as the...
Fierce Biotech · fiercebiotech.com · 2026-05-01 15:18 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 3Origin domains: 3Duplicates: -
Showing 3 / 0
Top publishers (this list)
- BioPharma Dive (1)
- Fierce Pharma (All) (1)
- Fierce Biotech (1)
Top origin domains (this list)
- biopharmadive.com (1)
- fiercepharma.com (1)
- fiercebiotech.com (1)